Malaysia to study Sinovac clinical trial data before approving vaccine
KUALA LUMPUR (Reuters) — Malaysia, which is negotiating the provision to China's Sinovac Biotech for a COVID-19 Vaccine, can only go on procurement if it complies with local regulators' protection and effectiveness requirements, the Minister said on Wednesday.
Brazil has raised questions over Sinovac's vaccination, but just 50.4 percent has been shown to be effective in avoiding symptomatic infections following clinical tests.
The results were announced in accordance with Indonesia's first inoculation of Sinovac's CoronaVac vaccine on Wednesday, one of the world's largest coronavirus vaccines.
First, Science, Technology and Innovation Minister Khairy Jamaluddin said on Twitter that Malaysia is going to study Sinovac's clinical results.
"If we are not satisfied with the safety and efficacy, we will not go through with the procurement," said Khairy.
On Tuesday, the Pharmaniaga Bhd in Malaysia reached an agreement with Sinovac to buy and produce 14 million doses of COVID-19 vaccine at home.
Malaysia has already held talks on a total of 23.9 million doses of COVID-19 vaccines with another Chinese producer, CanSino Biologics (CBC), and Russia's Gamaleia Institute, the maker of the Sputnik V vaccine.
This will include the U.S. and German pharmaceutical producers Pfizer and BioNTech and the British-Swedish AstraZeneca PLC.
(Joseph Sipalan reporting; Ed Davies editing)